VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that the current commercial relationship between Aequus and Sandoz regarding Glaucoma medication Vistitan™ will remain in place until February 2022. The two parties continue to discuss extending and expanding the relationship to potentially include additional products beyond Vistitan™ and Tacrolimus.